cd169 (Bio-Rad)
Bio-Rad is a verified supplier 
Bio-Rad manufactures this product 
94
Structured Review
Bio-Rad
cd169
Cd169, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 94/100, based on 55 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+cd169/Mouse+anti+Pig+CD169/bio_rxiv__64898__2026__04__22__719209-213-30-31
Average 94 stars, based on 55 article reviews
Cd169, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 94/100, based on 55 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+cd169/Mouse+anti+Pig+CD169/bio_rxiv__64898__2026__04__22__719209-213-30-31
Average 94 stars, based on 55 article reviews
cd169 - by Bioz Stars,
2026-10
94/100 stars
Images
Related Articles
other:Article Title: Sulfated glycosaminoglycans inhibit LCMV entry and modulate antiviral immunity and pathology Article Snippet: Cell Culture:Article Title: Dexamethasone enhances CD163 expression in porcine IPKM immortalized macrophages Article Snippet: The cells were seeded in 8-well chamber slides (2 × 10 5 cells/well) and treated with water-soluble DEX (FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan) in growth medium at the indicated concentrations. .. After being cultured for 1 or 3 days, they were fixed using 4% paraformaldehyde phosphate buffer solution (Nacalai Tesque, Inc., Kyoto, Japan) and immunostained using mouse monoclonal anti-CD163 (Bio-Rad, Hercules, CA) or Staining:Article Title: In vivo imaging of inflammasome activation reveals a subcapsular macrophage burst response that mobilizes innate and adaptive immunity. Article Snippet: .. Cell-surface staining was performed with the following antibodies, all from Biolegend and at a dilution of 1:200 (0.5 μg/mL) unless otherwise specified, in the presence of blocking anti-CD16/32 (eBioscience, clone 93) and after exclusion of doublets and dead cells (live/dead fixable dyes, Invitrogen): anti-CD3 (17A2), anti-NK.1.1 (PK136), anti-CD8 (53-6.7), anti-CD19 (1D3), Blocking Assay:Article Title: In vivo imaging of inflammasome activation reveals a subcapsular macrophage burst response that mobilizes innate and adaptive immunity. Article Snippet: .. Cell-surface staining was performed with the following antibodies, all from Biolegend and at a dilution of 1:200 (0.5 μg/mL) unless otherwise specified, in the presence of blocking anti-CD16/32 (eBioscience, clone 93) and after exclusion of doublets and dead cells (live/dead fixable dyes, Invitrogen): anti-CD3 (17A2), anti-NK.1.1 (PK136), anti-CD8 (53-6.7), anti-CD19 (1D3), In Vitro:Article Title: Targeting of antigen presenting cells with immunonanotherapeutics Article Snippet: .. In a preferred embodiment, the in vitro assay that accompanies the in vivo assay determines the immobilization of human or murine dendritic cells or murine subcapsular sinus macrophages (collectively “In Vitro Antigen Presenting Cells”) on a biocompatible surface that is coated with either the moieties of which the immunofeature surface is comprised, or an antibody that is specific for an In Vitro Antigen Presenting Cell-expressed surface antigen (for human dendritic cells: anti-CD1c (BDCA-1) clone AD5-8E7 from Miltenyi BIOTEC®, for mouse dendritic cells: anti-CD11c is (αX integrin) clone HL3, BD BIOSCIENCES®, or for murine subcapsular sinus macrophages: Article Title: Adjuvant incorporation in immunoanotherapeutics Article Snippet: In a preferred embodiment, the in vitro assay that accompanies the in vivo assay determines the immobilization of human or murine dendritic cells or murine subcapsular sinus macrophages (collectively “In Vitro Antigen Presenting Cells”) on a biocompatible surface that is coated with either the moieties of which the immunofeature surface is comprised, or an antibody that is specific for an In Vitro Antigen Presenting Cell-expressed surface antigen (for human dendritic cells: anti-CD1c (BDCA-1) clone AD5-8E7 from Miltenyi BIOTEC®, for mouse dendritic cells: anti-CD11c (αX integrin) clone HL3, BD BIOSCIENCES®, or for murine subcapsular sinus macrophages: anti-CD169 clone 3D6.112 for SEROTEC®) such that (i) an optimal coating density corresponding to maximal immobilization of the In Vitro Antigen Presenting Cells to the surface which has been coated with the moieties of which the immunofeature surface is comprised is either undetectable or at least 10%, preferably at least 20%, more preferably at least 25%, of that observed with the antibody coated surface; and (ii) if immobilization of In Vitro Antigen Presenting Cells by the immunofeature surface is detectable, the immunofeature surface that is being tested supports half maximal binding at a coating density of moieties of which the immunofeature surface is comprised that is at least 2-fold, preferably at lest 3-fold, more preferably at least 4-fold higher than the antibody coating density that supports half maximal binding. .. In a preferred embodiment, the in vitro assay that accompanies the in vivo assay determines the immobilization of human or murine dendritic cells or murine subcapsular sinus macrophages (collectively “In Vitro Antigen Presenting Cells”) on a biocompatible surface that is coated with either the moieties of which the immunofeature surface is comprised, or an antibody that is specific for an In Vitro Antigen Presenting Cell-expressed surface antigen (for human dendritic cells: anti-CD1c (BDCA-1) clone AD5-8E7 from Miltenyi BIOTEC®, for mouse dendritic cells: anti-CD11c (αX integrin) clone HL3, BD BIOSCIENCES®, or for murine subcapsular sinus macrophages: In Vivo:Article Title: Targeting of antigen presenting cells with immunonanotherapeutics Article Snippet: .. In a preferred embodiment, the in vitro assay that accompanies the in vivo assay determines the immobilization of human or murine dendritic cells or murine subcapsular sinus macrophages (collectively “In Vitro Antigen Presenting Cells”) on a biocompatible surface that is coated with either the moieties of which the immunofeature surface is comprised, or an antibody that is specific for an In Vitro Antigen Presenting Cell-expressed surface antigen (for human dendritic cells: anti-CD1c (BDCA-1) clone AD5-8E7 from Miltenyi BIOTEC®, for mouse dendritic cells: anti-CD11c is (αX integrin) clone HL3, BD BIOSCIENCES®, or for murine subcapsular sinus macrophages: Article Title: Adjuvant incorporation in immunoanotherapeutics Article Snippet: In a preferred embodiment, the in vitro assay that accompanies the in vivo assay determines the immobilization of human or murine dendritic cells or murine subcapsular sinus macrophages (collectively “In Vitro Antigen Presenting Cells”) on a biocompatible surface that is coated with either the moieties of which the immunofeature surface is comprised, or an antibody that is specific for an In Vitro Antigen Presenting Cell-expressed surface antigen (for human dendritic cells: anti-CD1c (BDCA-1) clone AD5-8E7 from Miltenyi BIOTEC®, for mouse dendritic cells: anti-CD11c (αX integrin) clone HL3, BD BIOSCIENCES®, or for murine subcapsular sinus macrophages: anti-CD169 clone 3D6.112 for SEROTEC®) such that (i) an optimal coating density corresponding to maximal immobilization of the In Vitro Antigen Presenting Cells to the surface which has been coated with the moieties of which the immunofeature surface is comprised is either undetectable or at least 10%, preferably at least 20%, more preferably at least 25%, of that observed with the antibody coated surface; and (ii) if immobilization of In Vitro Antigen Presenting Cells by the immunofeature surface is detectable, the immunofeature surface that is being tested supports half maximal binding at a coating density of moieties of which the immunofeature surface is comprised that is at least 2-fold, preferably at lest 3-fold, more preferably at least 4-fold higher than the antibody coating density that supports half maximal binding. .. In a preferred embodiment, the in vitro assay that accompanies the in vivo assay determines the immobilization of human or murine dendritic cells or murine subcapsular sinus macrophages (collectively “In Vitro Antigen Presenting Cells”) on a biocompatible surface that is coated with either the moieties of which the immunofeature surface is comprised, or an antibody that is specific for an In Vitro Antigen Presenting Cell-expressed surface antigen (for human dendritic cells: anti-CD1c (BDCA-1) clone AD5-8E7 from Miltenyi BIOTEC®, for mouse dendritic cells: anti-CD11c (αX integrin) clone HL3, BD BIOSCIENCES®, or for murine subcapsular sinus macrophages: Binding Assay:Article Title: Targeting of antigen presenting cells with immunonanotherapeutics Article Snippet: .. In a preferred embodiment, the in vitro assay that accompanies the in vivo assay determines the immobilization of human or murine dendritic cells or murine subcapsular sinus macrophages (collectively “In Vitro Antigen Presenting Cells”) on a biocompatible surface that is coated with either the moieties of which the immunofeature surface is comprised, or an antibody that is specific for an In Vitro Antigen Presenting Cell-expressed surface antigen (for human dendritic cells: anti-CD1c (BDCA-1) clone AD5-8E7 from Miltenyi BIOTEC®, for mouse dendritic cells: anti-CD11c is (αX integrin) clone HL3, BD BIOSCIENCES®, or for murine subcapsular sinus macrophages: Article Title: Adjuvant incorporation in immunoanotherapeutics Article Snippet: In a preferred embodiment, the in vitro assay that accompanies the in vivo assay determines the immobilization of human or murine dendritic cells or murine subcapsular sinus macrophages (collectively “In Vitro Antigen Presenting Cells”) on a biocompatible surface that is coated with either the moieties of which the immunofeature surface is comprised, or an antibody that is specific for an In Vitro Antigen Presenting Cell-expressed surface antigen (for human dendritic cells: anti-CD1c (BDCA-1) clone AD5-8E7 from Miltenyi BIOTEC®, for mouse dendritic cells: anti-CD11c (αX integrin) clone HL3, BD BIOSCIENCES®, or for murine subcapsular sinus macrophages: anti-CD169 clone 3D6.112 for SEROTEC®) such that (i) an optimal coating density corresponding to maximal immobilization of the In Vitro Antigen Presenting Cells to the surface which has been coated with the moieties of which the immunofeature surface is comprised is either undetectable or at least 10%, preferably at least 20%, more preferably at least 25%, of that observed with the antibody coated surface; and (ii) if immobilization of In Vitro Antigen Presenting Cells by the immunofeature surface is detectable, the immunofeature surface that is being tested supports half maximal binding at a coating density of moieties of which the immunofeature surface is comprised that is at least 2-fold, preferably at lest 3-fold, more preferably at least 4-fold higher than the antibody coating density that supports half maximal binding. .. In a preferred embodiment, the in vitro assay that accompanies the in vivo assay determines the immobilization of human or murine dendritic cells or murine subcapsular sinus macrophages (collectively “In Vitro Antigen Presenting Cells”) on a biocompatible surface that is coated with either the moieties of which the immunofeature surface is comprised, or an antibody that is specific for an In Vitro Antigen Presenting Cell-expressed surface antigen (for human dendritic cells: anti-CD1c (BDCA-1) clone AD5-8E7 from Miltenyi BIOTEC®, for mouse dendritic cells: anti-CD11c (αX integrin) clone HL3, BD BIOSCIENCES®, or for murine subcapsular sinus macrophages: Single Cell:Article Title: B Cell‐Mediated Maintenance of Cluster of Differentiation 169–Positive Cells Is Critical for Liver Regeneration Article Snippet: Snap‐frozen tissue sections were stained with antibodies: CD169 (clone MOMA‐1; ABD Serotec, Dusseldorf, Germany), B220 (eBioscience, San Diego, CA), Ki‐67 (Abcam), phospho‐histone H3 (phospho‐H3; Millipore). .. Different immune populations were identified in single‐cell solutions from naive liver and spleen samples and spleen and liver samples newly regenerated (“new”) and remaining lobes (“old”) 24 and 48 hours after PHx using anti‐B220, anti‐CD21, anti‐CD23, anti–progammed death ligand 1, anti‐NK1.1, anti‐CD3, anti‐CD19, anti‐CD11b, anti‐Siglec‐H, anti‐CD8a, and anti‐CD11c antibodies; anti–major histocompatibility complex class II; and anti‐CD40, anti‐CD80, anti‐CD86, anti‐F4/80, anti‐Ly6C, anti‐CD138, anti–immunoglobulin M, anti‐CD38, anti‐CD62L, anti‐CD5, anti‐IgD, anti‐CD1d antibodies, and 7‐amino‐actinomycin D. All antibodies were obtained from eBioscience, except |
